1. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia
- Author
-
Patrick W. Burke, Stephen M Clark, Marissa Olson, Tapan M. Kadia, Dale L. Bixby, Carissa Treptow, Shawn Griffin, Bernard L. Marini, Kelley L Ratermann, Caitlin R. Rausch, Lydia L. Benitez, Mallory Crain, Anthony J. Perissinotti, Kristen Pettit, Michael Filtz, and Jeff Klaus
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Daunorubicin ,Secondary AML ,03 medical and health sciences ,0302 clinical medicine ,High dose cytarabine ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,polycyclic compounds ,medicine ,Humans ,Secondary Acute Myeloid Leukemia ,In patient ,neoplasms ,Retrospective Studies ,business.industry ,organic chemicals ,Cytarabine ,Hematology ,Liposomal daunorubicin ,carbohydrates (lipids) ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,FLAG (chemotherapy) ,business ,030215 immunology ,medicine.drug - Abstract
Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 against regimens containing a purine analogue and high-dose cytarabine (HIDAC). This retrospective study compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based regimens and CPX-351 in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% in the HIDAC-based therapy arm vs. 47.9% in the CPX-351 arm (
- Published
- 2021